This was not surprising to us as the anti-cancer/anti-angiogenic PEDF peptide p18 does not markedly alter PC-3 cell viability while still maintaining an in vivo potency [39], however, the result could also be due to variability inherent to PEDF preparations [70]. The gene discussed is SERPINF1; the disease is cancer.